J. Goeminne

18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)

Sigrid Stroobants, J. Goeminne, M. Seegers et al. · European Journal of Cancer · 2003 · 526 citations

Medicine, Nuclear Medicine, Oncology +10

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

José Baselga, Patricia Gómez, Richard Greil et al. · Journal of Clinical Oncology · 2013 · 351 citations · Full text

Medicine, Oncology, Pharmacology +17

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Luca Gianni, Anna Lladó, Giulia Bianchi et al. · Journal of Clinical Oncology · 2010 · 269 citations

Medicine, Oncology, Pharmacology +17

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program

Charles Van Praet, Sylvie Rottey, Fransien Van Hende et al. · Urologic Oncology Seminars and Original Investigations · 2016 · 13 citations · Full text

Medicine, Oncology, Urology +16